HK1053792A1 - Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis - Google Patents

Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis

Info

Publication number
HK1053792A1
HK1053792A1 HK03105681A HK03105681A HK1053792A1 HK 1053792 A1 HK1053792 A1 HK 1053792A1 HK 03105681 A HK03105681 A HK 03105681A HK 03105681 A HK03105681 A HK 03105681A HK 1053792 A1 HK1053792 A1 HK 1053792A1
Authority
HK
Hong Kong
Prior art keywords
histamines
leukotriene
conjunctivitis
influence
action
Prior art date
Application number
HK03105681A
Other languages
English (en)
Inventor
Hildegard Kuss
Jurgen Engel
Istvan Szelenyi
Original Assignee
Viatris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris Gmbh filed Critical Viatris Gmbh
Publication of HK1053792A1 publication Critical patent/HK1053792A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK03105681A 2000-02-17 2003-08-08 Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis HK1053792A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10007203A DE10007203A1 (de) 2000-02-17 2000-02-17 Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
PCT/EP2001/001190 WO2001060407A2 (fr) 2000-02-17 2001-02-05 Nouvelle combinaison d'antihistaminiques non sedatifs et de substances qui influencent l'effet du leucotriene, pour le traitement de la rhinite/conjonctivite

Publications (1)

Publication Number Publication Date
HK1053792A1 true HK1053792A1 (en) 2003-11-07

Family

ID=7631276

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03105681A HK1053792A1 (en) 2000-02-17 2003-08-08 Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis

Country Status (27)

Country Link
US (1) US6436924B2 (fr)
EP (1) EP1265615B1 (fr)
JP (1) JP5529362B2 (fr)
KR (1) KR100764329B1 (fr)
CN (1) CN1241569C (fr)
AR (1) AR027528A1 (fr)
AT (1) ATE287266T1 (fr)
AU (1) AU781177B2 (fr)
BR (1) BR0108445A (fr)
CZ (1) CZ296395B6 (fr)
DE (2) DE10007203A1 (fr)
DK (1) DK1265615T3 (fr)
ES (1) ES2236189T3 (fr)
HK (1) HK1053792A1 (fr)
HU (1) HU228927B1 (fr)
IL (2) IL151106A0 (fr)
MX (1) MXPA02008064A (fr)
NO (1) NO328153B1 (fr)
NZ (1) NZ520470A (fr)
PL (1) PL198357B1 (fr)
PT (1) PT1265615E (fr)
RU (1) RU2292208C2 (fr)
SK (1) SK285990B6 (fr)
TW (1) TWI296525B (fr)
UA (1) UA72587C2 (fr)
WO (1) WO2001060407A2 (fr)
ZA (1) ZA200206575B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2373186A (en) * 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
FR2833493B1 (fr) * 2001-12-18 2005-09-23 Ioltechnologie Production Forme galenique solide et soluble pour l'administration occulaire de principes actifs et procede de fabrication d'un insert ophtalmique solide et soluble
WO2003101434A2 (fr) * 2001-12-21 2003-12-11 Sampad Bhattacharya Compositions pharmaceutiques intranasales comprenant un antihistaminique et un inhibiteur de leucotrienes
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
WO2005027886A2 (fr) * 2003-09-17 2005-03-31 Decode Genetics Ehf. Methodes de prevention ou de traitement de la recurrence de l'infarctus du myocarde
AU2003301305A1 (en) * 2002-10-17 2004-05-04 Decode Genetics Ehf. Susceptibility gene for myocardial infarction; methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
WO2004069338A1 (fr) * 2003-01-31 2004-08-19 Schering Corporation Utilisation de combinaisons d'antagonistes du recepteur h1 et h3 de l'histamine pour la preparation d'un medicament destine au traitement d'etats cutanes et oculaires d'origine allergique
US20040235807A1 (en) * 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
WO2005030331A1 (fr) * 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Traitement antihistaminique combine
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
EP1713473B1 (fr) * 2004-02-06 2013-03-13 MEDA Pharma GmbH & Co. KG Combinaison d'anticholinergiques et de glucocorticoides pour le traitement prolonge de l'asthme et des broncho-pneumopathies chroniques obstructives
PT1713471E (pt) * 2004-02-06 2012-04-10 Meda Pharma Gmbh & Co Kg Combinação de anticolinérgicos e inibidores de fosfodiesterase tipo 4 para o tratamento de doenças respiratórias
PE20060484A1 (es) * 2004-07-14 2006-07-06 Ucb Farchim Sa Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
ES2704482T3 (es) 2004-11-24 2019-03-18 Meda Pharmaceuticals Inc Composiciones que comprenden azelastina y sus métodos de uso
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
JP4991693B2 (ja) * 2005-03-16 2012-08-01 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 呼吸器疾患の治療のための抗コリン作用薬及びロイコトリエン受容体アンタゴニストの組み合わせ剤
US7405302B2 (en) * 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
AU2006329042B2 (en) 2005-12-21 2012-02-02 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases
WO2007126865A2 (fr) * 2006-03-30 2007-11-08 Patrin Pharma Administration nasale d'antagonistes de leukotriènes
WO2008067566A1 (fr) 2006-11-30 2008-06-05 Amira Pharmaceuticals, Inc. Compositions et traitements comprenant des inhibiteurs de la protéine activant la 5-lipoxygénase et des modulateurs de l'oxyde nitrique
ATE534390T1 (de) * 2007-11-19 2011-12-15 Bausch & Lomb Verwendung von levocabastin zur modulierung der erzeugung von proinflammatorischen zytokinen
US9254286B2 (en) 2009-03-17 2016-02-09 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
CA2754996A1 (fr) * 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Formulations ophtalmiques de ketotifene et procedes d'utilisation
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
MY198422A (en) 2009-04-29 2023-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
KR101418404B1 (ko) * 2012-01-06 2014-07-10 한미약품 주식회사 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제
CA2901421A1 (fr) 2013-03-13 2014-10-09 Bruce Chandler May Utilisation de levocetirizine et de montelukast dans le traitement des maladies auto-immunes
NZ712180A (en) 2013-03-13 2017-01-27 Flatley Discovery Lab Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis
KR101555908B1 (ko) * 2013-12-19 2015-09-25 한미약품 주식회사 몬테루카스트 또는 이의 약제학적으로 허용 가능한 염을 포함하는 액상 제제 및 이의 제조방법
EP3102209B1 (fr) 2014-02-04 2021-04-07 Bioscience Pharma Partners, LLC Utilisation d'inhibiteurs de flap pour réduire une lésion liée à une neuro-inflammation du système nerveux central
WO2016044095A1 (fr) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Lévocétirizine et montélukast dans le traitement de troubles médiés par une inflammation
JP2022517316A (ja) * 2019-01-11 2022-03-08 ネイジス ファーマシューティカルズ インコーポレイテッド ロイコトリエン合成阻害剤
CN110721189A (zh) * 2019-11-19 2020-01-24 贵州云峰药业有限公司 一种皮肤消毒剂
IL295262A (en) * 2020-02-03 2022-10-01 Taro Pharma Ind Montelukast transdermal formulation
CN116284470B (zh) * 2023-02-15 2024-08-02 广西中医药大学 一种海蛇尾多糖硫酸酯衍生物的制备方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3813384A (en) 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
ES2053678T3 (es) 1987-11-13 1994-08-01 Asta Medica Ag Procedimiento para preparar un medicamento con contenido de azelastina para la aplicacion nasal y/u ocular.
EP0345931B1 (fr) 1988-04-27 1993-01-20 Schering Corporation Certains mélanges PAF antagonistes/antihistamine et procédés
WO1994003170A1 (fr) * 1992-08-03 1994-02-17 Sepracor Inc. Metabolites de terfenadine et leurs isomeres optiquement purs utilises dans le traitement des affections allergiques
EE9800234A (et) * 1996-02-08 1998-12-15 Merck & Co., Inc. Ravimeetod ja farmatseutiline kompositsioon
DE19610882A1 (de) * 1996-03-20 1997-09-25 Dresden Arzneimittel Neue 1,3,5-trisubstituierte Indazol-Derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
EP0979105A1 (fr) * 1997-04-30 2000-02-16 Warner-Lambert Company Compositions antiinflammatoires pour application nasale topique
US6242179B1 (en) 1997-12-17 2001-06-05 Incyte Pharmaceuticals, Inc. Human phosphatases
HUP0101369A3 (en) * 1997-12-23 2002-11-28 Schering Corp Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
US6194431B1 (en) * 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors

Also Published As

Publication number Publication date
RU2292208C2 (ru) 2007-01-27
NO20023818D0 (no) 2002-08-12
KR20020083161A (ko) 2002-11-01
CZ20022700A3 (cs) 2002-11-13
US6436924B2 (en) 2002-08-20
RU2002123345A (ru) 2004-03-20
HUP0204079A3 (en) 2006-07-28
BR0108445A (pt) 2003-04-01
SK285990B6 (sk) 2008-01-07
NO20023818L (no) 2002-08-12
AU781177B2 (en) 2005-05-12
DK1265615T3 (da) 2005-05-30
EP1265615A2 (fr) 2002-12-18
ZA200206575B (en) 2003-05-14
UA72587C2 (uk) 2005-03-15
NZ520470A (en) 2004-05-28
KR100764329B1 (ko) 2007-10-05
NO328153B1 (no) 2009-12-21
AR027528A1 (es) 2003-04-02
WO2001060407A3 (fr) 2002-03-07
US20010025040A1 (en) 2001-09-27
HU228927B1 (en) 2013-06-28
AU4058401A (en) 2001-08-27
MXPA02008064A (es) 2004-04-05
CZ296395B6 (cs) 2006-03-15
ATE287266T1 (de) 2005-02-15
IL151106A0 (en) 2003-04-10
JP2003522803A (ja) 2003-07-29
HUP0204079A2 (hu) 2003-04-28
PL198357B1 (pl) 2008-06-30
TWI296525B (en) 2008-05-11
CN1241569C (zh) 2006-02-15
DE10007203A1 (de) 2001-08-23
DE50105126D1 (de) 2005-02-24
IL151106A (en) 2008-06-05
CN1400903A (zh) 2003-03-05
WO2001060407A2 (fr) 2001-08-23
JP5529362B2 (ja) 2014-06-25
EP1265615B1 (fr) 2005-01-19
PL355818A1 (en) 2004-05-17
SK11752002A3 (sk) 2002-11-06
PT1265615E (pt) 2005-05-31
ES2236189T3 (es) 2005-07-16

Similar Documents

Publication Publication Date Title
IL151106A0 (en) Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis
EP1496878A4 (fr) Techniques d'identification de modulateurs d'angiogenese, composes decouverts par ces techniques et techniques de traitement utilisant ces composes
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
AP2006003558A0 (en) Polymorphic forms of 3-(4-amino-1oxo-1,3 dilhydro-isoindol-2-yl)-piperidine-2,6-dione.
EP1274444A4 (fr) Composes servant a traiter des troubles psychiatriques ou des troubles provoques par la consommation abusive de substances psychoactives
ZA200109073B (en) Compositions for treatment of disorders of the oesophagus.
ZA200204830B (en) Novel method for down-regulation of amyloid.
HK1047425A1 (en) Garbage treatment apparatus.
HK1057363A1 (en) Ccr5 antagonists useful for treating aids.
HK1060118A1 (en) (S)-4-amino-5-chloro-2-methoxy-n-Ä1-Ä1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethylÜ-4-piperidinylÜbenzamide for treating gastrointestinal motility disorders.
EP1465968A4 (fr) Procedes de traitement de distillat desodorisant
HK1050549A1 (en) Heater.
MXPA03001717A (es) METODO PARA EL TRATAMIENTO DE LA MIGRAnA.
HK1064261A1 (en) Method for the treatment of tobacco.
MXPA03005673A (es) Inhibidores de 8-arilquinolin-fosfodiesterasa-4-substituidos.
MXPA02012907A (es) Procedimiento para encontrar compuestos que son adecuados para el tratamiento y/o la profilaxia de la obesidad.
IL153559A0 (en) Compounds for treating impaired fundic relaxation
GB0422769D0 (en) Methods for treating deodorizer distillate
MXPA03002517A (es) Proceso de hidrofisuracion.
SI1265615T1 (en) Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis
MXPA03004195A (es) Terapia combinada para los trastornos dependientes de estrogenos.
MXPA02000714A (es) Aparato para triturar material.
EP1701470A4 (fr) Dispositif d'acces a large bande et son procede pour la commande d'un agent de relais dhcp
ITPD20000203A0 (it) Dispositivi di sicurezza per portoni sezionali.
TW479626U (en) Treatment device for junk

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170205